TG Therapeutics Inc. (NASDAQ:TGTX) is a biopharmaceutical company built on a vision to transform the treatment landscape for autoimmune and B-cell mediated diseases through highly targeted, clinically differentiated therapies. Founded with the goal of advancing innovative monoclonal antibodies and next-generation immunotherapies, the company has spent over a decade establishing itself as a formidable player in the biotechnology sector. Its mission has always been centered on delivering more effective, more convenient, and more accessible treatment options for patients living with chronic and often debilitating immune-driven illnesses. Over the years, TG Therapeutics evolved from a development-stage biotech with a bold scientific thesis into a fully commercial enterprise with a growing international footprint and a rapidly expanding revenue base.
The company’s background is defined by its relentless commitment to scientific innovation, particularly within the realm of B-cell biology. This strategic focus led to the development of ublituximab, an anti-CD20 monoclonal antibody engineered to deliver high potency with a more convenient administration profile. TG Therapeutics’ research heritage is rooted in understanding the critical role of B-cells in autoimmune conditions such as multiple sclerosis, which later became central to the company’s flagship therapy. Years of clinical development produced a robust pipeline supported by strong efficacy results, durable safety data, and innovative dosing regimens that would eventually differentiate the company from larger competitors in the MS market. Its scientific foundation reflects a blend of advanced immunology, optimized antibody engineering, and a commitment to developing therapies that meaningfully improve the patient experience.
A major turning point in the company’s history came with the approval and commercialization of BRIUMVI, the first and only monoclonal antibody for relapsing forms of multiple sclerosis that can be administered in a one-hour infusion. This milestone marked TG Therapeutics’ transition from a research-driven organization into a fully operational commercial biopharma company capable of competing with global giants in the neurology and autoimmune treatment markets. The approval of BRIUMVI was the result of years of clinical trials, regulatory engagement, and strategic investment, demonstrating the company’s ability not only to innovate scientifically but also to execute commercially. Its entry into the MS space was immediately notable for challenging long-established infusion therapies by offering a faster, more flexible, and more efficient treatment option for patients and infusion centers alike.
TG Therapeutics’ growth accelerated as BRIUMVI began gaining traction across the United States, supported by strong payer coverage and rising physician adoption. The company expanded its global reach through strategic partnerships, enabling the therapy’s approval in major international markets including the European Union, the United Kingdom, Switzerland, Australia, Kuwait, and the United Arab Emirates. This rapid commercialization highlighted the strength of TG Therapeutics’ global strategy and its ability to work collaboratively with international regulators, distribution partners, and health systems. The company’s background is shaped not only by its scientific achievements but also by its ability to scale commercially, respond to market needs, and build a sustainable global business model around a differentiated therapeutic product.
In addition to its commercial success, TG Therapeutics has continued broadening its scientific pipeline, advancing Phase 3 studies for subcutaneous ublituximab and investigating new dosing strategies to improve treatment accessibility and convenience. This commitment to ongoing innovation underscores the company’s philosophy that scientific progress does not end with a single approval but continues through iterative development, real-world data collection, and expanded indications. The company’s background reflects a disciplined, forward-looking strategy rooted in sustained investment in research, clinical development, and market expansion.
Today, TG Therapeutics stands as a rapidly growing biopharmaceutical company defined by its scientific rigor, commercial execution, and strategic vision. From its early focus on B-cell immunology to its rise as a major competitor in the global multiple sclerosis market, the company’s journey reflects resilience, innovation, and the ability to deliver therapies that shape the future of autoimmune disease treatment. Its background is a story of scientific ambition translated into real-world impact, positioning TG Therapeutics as a powerful emerging leader in neurology and immunology.
TG Therapeutics (TGTX) Strengthens Its Position as a High-Growth Biopharma Leader as BRIUMVI Revenue Surges and 2025 Guidance Increases
TG Therapeutics Inc. (NASDAQ:TGTX) stands at the center of one of the most powerful growth trajectories in the biotechnology sector, driven by the exceptional commercial performance of its first-in-class MS therapy BRIUMVI and the company’s deepening commitment to innovation, operational discipline, and shareholder value creation. With third-quarter 2025 revenue soaring to $161.7 million and BRIUMVI U.S. net revenue hitting an impressive $152.9 million, TG Therapeutics is demonstrating that it has shifted from an emerging biotech player into a commercial powerhouse with accelerating market penetration, expanding global reach, and a financial profile that continues to strengthen every quarter.
The third-quarter earnings report represents one of the most pivotal moments for TG Therapeutics, not only because it exceeded expectations, but because the company raised its full-year 2025 global revenue target to $600 million and increased its full-year BRIUMVI U.S. net revenue target to approximately $585 million. These upgraded forecasts underscore the explosive demand for BRIUMVI and highlight the durability of the company’s commercial strategy. In the competitive landscape of multiple sclerosis therapies—spanning anti-CD20 monoclonal antibodies, high-efficacy biologics, and long-established MS treatments—BRIUMVI is emerging as one of the fastest-growing products in the segment, supported by differentiating clinical attributes and strong real-world adoption.
CHECK THIS OUT: Corcept (CORT) Skyrockets 1,534% in 10 Years and Immuneering (IMRX) Reports 86% 9-Month Survival in Pancreatic Cancer.
Revenue Growth Accelerates as BRIUMVI Emerges as a Leading Anti-CD20 Therapy for Multiple Sclerosis
The heart of TG Therapeutics’ bullish momentum lies in the unparalleled growth trajectory of BRIUMVI, whose revenue increased 84 percent over the same period in 2024 and 10 percent sequentially over Q2 2025. With U.S. net product revenue reaching nearly $153 million in a single quarter, BRIUMVI is solidifying its status as a disruptive force in the MS treatment market. Physicians and infusion centers are increasingly embracing BRIUMVI due to its rapid one-hour infusion time, powerful efficacy demonstrated in pivotal clinical trials, and consistent safety results even in long-term exposure. This accelerated adoption is reflected in both prescription numbers and payer coverage expansion, which continues to lower barriers for new patients.
Beyond the United States, TG Therapeutics is rapidly transforming BRIUMVI into a global MS franchise. The company’s partnership with Neuraxpharm has already resulted in approvals across the European Union, the United Kingdom, Switzerland, Australia, Kuwait, and the United Arab Emirates. With ex-U.S. revenue beginning to contribute ($6.4 million this quarter), the global commercialization footprint is poised to multiply in the coming years as new markets are unlocked and international physicians gain clinical confidence through real-world evidence and data from long-term extension studies.
New Clinical Data Strengthens BRIUMVI’s Position as a Long-Term MS Therapy With Deep Market Potential
TG Therapeutics’ bullish thesis becomes even stronger when considering the new data presented at the 2025 ECTRIMS annual meeting. Six-year extension data from the ULTIMATE I & II trials demonstrated that an impressive 89.9 percent of relapsing MS patients remained free from 24-week confirmed disability progression after extended continuous BRIUMVI treatment. This long-term stability, paired with a safety profile that remained consistent with no new safety signals emerging, reinforces BRIUMVI’s potential as a long-duration, high-efficacy therapy capable of retaining patients for many treatment cycles.
The ENHANCE trial update provided equally important insight, showing that consolidating the Day 1 (150 mg) and Day 15 (450 mg) infusions into a single 600 mg dose was well tolerated and could simplify the treatment process for both patients and infusion centers. This streamlined dosing regimen is already being tested in a double-blinded, randomized, label-enabling trial, which could lead to expanded dosing flexibility and increased market penetration.
The ENABLE real-world observational study further validates the real-world experience of BRIUMVI, showing outcomes consistent with pivotal studies. Real-world evidence has become one of the strongest drivers of physician adoption in the MS community, and ENABLE helps solidify confidence among neurologists who are switching patients from older therapies to BRIUMVI.
TG Therapeutics Expands Its Pipeline With Multiple Phase 3 Programs That Strengthen Long-Term Growth
While BRIUMVI is already generating near-megablockbuster revenue, the pipeline behind it offers substantial upside potential. TG Therapeutics has commenced patient enrollment into its Phase 3 pivotal program for subcutaneous ublituximab, a formulation with potential for higher convenience and competitive positioning in the increasingly important SC biologics segment. The company also completed patient enrollment in the randomized Phase 3 program evaluating its consolidated dosing regimen for IV BRIUMVI. These studies could support expanded labels, improved market share, and wider physician adoption.
Beyond MS, TG Therapeutics is advancing its presence in autoimmune disease through the ongoing Phase 1 clinical trial evaluating azer-cel in progressive multiple sclerosis. Each of these programs represents an extension of the core TG Therapeutics vision: to establish a dominant presence in autoimmune biologics by offering high-efficacy treatments with improved administration profiles and strong safety outcomes.
A Powerful Share Repurchase Program Signals Strong Confidence in TG Therapeutics’ Long-Term Valuation
Investors have taken notice of the company’s strengthened financial profile, and TG Therapeutics reinforced this confidence through its $100 million share repurchase program. The repurchase of approximately 3.5 million shares at an average price of $28.55 per share sends a clear message that management believes TGTX is materially undervalued relative to its revenue growth, operational momentum, and expanding pipeline. The authorization of an additional $100 million repurchase program further magnifies this conviction and offers shareholders a tangible return mechanism that enhances per-share value.
Third Quarter 2025 Financial Results Demonstrate Strong Execution and Path Toward Sustained Profitability
TG Therapeutics’ financial results illustrate a company in the midst of a powerful commercial inflection. Net income surged to $390.9 million for the quarter, buoyed by a $365 million one-time income tax benefit driven by the release of a deferred tax asset valuation allowance. Even without this non-recurring benefit, profitability metrics strengthened meaningfully due to BRIUMVI’s rapidly expanding gross revenue base. Total product revenue reached $159.3 million for the quarter and $417.8 million year-to-date, more than doubling from 2024 levels.
R&D expenses rose due to expanded clinical activity, manufacturing scale-up, and development of new formulations, while SG&A expenses increased primarily due to marketing and commercial expansion initiatives. These investments are consistent with the company’s aggressive push toward global market penetration and broader therapeutic dominance.
With cash, cash equivalents, and investment securities totaling $178.3 million and projected revenue sufficient to fund operations, TG Therapeutics enters 2026 in an exceptionally strong cash position. The company affirmed that its current resources, combined with expected BRIUMVI sales, are enough to support ongoing operations without the need for dilutive financing.
TG Therapeutics Positions Itself as a Dominant Force in the Global MS Market
TG Therapeutics’ bullish narrative is deeply rooted in the unparalleled momentum of BRIUMVI, transformative clinical data, expanding global approvals, and a growing body of real-world evidence that reinforces long-term safety and efficacy. With raised revenue guidance, powerful prescription momentum, advancing Phase 3 programs, and a confident share repurchase strategy, TG Therapeutics is shaping itself into one of the most compelling mid-cap biopharma growth stories in the market. For investors seeking exposure to a rapidly scaling commercial-stage biotechnology company with strong fundamentals and expanding global opportunity, TG Therapeutics stands out as a top-tier candidate poised for significant upside.
READ ALSO: Tiziana (TLSA) Surges 143% in 2025 and Immuneering (IMRX) Reports 86% 9-Month Survival in Pancreatic Cancer.
